<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183843</url>
  </required_header>
  <id_info>
    <org_study_id>0546-2015-0011</org_study_id>
    <nct_id>NCT03183843</nct_id>
  </id_info>
  <brief_title>Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses</brief_title>
  <official_title>The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of anticoagulation therapy using dabigatran in comparison with
      warfarin will be evaluated in patients with atrial fibrillation after mitral valve prosthetic
      replacement concomitant with Cox-Maze procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with prosthetic mitral valves need a long-term anticoagulation therapy. After mitral
      valve replacement using mechanical prostheses warfarin is administrated during the whole
      life. Biological prostheses allows do discontinue anticoagulation 3 months after surgery in
      the absence of other risk factors of thrombosis especially atrial fibrillation. The common
      approach to patients with mitral valve disease and atrial fibrillation is mitral valve
      prosthetic replacement concomitant to Cox-Maze procedure. This allows to maintain sinus
      rhythm in 65-80% of patients. In the study the safety and efficacy of dabigatran in
      comparison with warfarin will be evaluated after the mitral valve surgery and Cox-Maze
      procedure.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>Thrombosis of prosthetic valve, transient ischemic attack, stroke, myocardial infarction, pulmonary and systemic thromboembolic events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>Massive symptomatic intracranial, intraocular, retroperitoneal, intraarticular, pericardial bleeding or intramuscular bleeding associated with compressive syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Mitral Valve Stenosis and Insufficiency</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabigatran etexilate 150 mg by mouth every 12 hours for a year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate</intervention_name>
    <description>Dabigatran Etexilate 150 mg capsules for oral administration twice a day</description>
    <arm_group_label>Dabigatran</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin 2.5 mg tablets for oral administration once a day</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mitral valve disease;

          -  atrial fibrillation;

          -  mitral valve prosthetic replacement with concomitant Cox-Maze Procedure;

          -  18-75 years of age;

          -  signed informed consent form.

        Exclusion Criteria:

          -  mechanical valve replacement;

          -  repeated mitral valve surgery;

          -  coronary artery hemodynamically significant stenoses;

          -  ventricular arrhythmias;

          -  creatinine clearance &lt;50 ml/min;

          -  HAS-BLED score &gt;3;

          -  previous stroke or transient ischemic attack;

          -  liver diseases;

          -  neoplasia;

          -  pregnancy;

          -  simultaneous antiplatelet therapy;

          -  allergic reactions on Dabigatran or Warfarin;

          -  cognitive disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yevgeny V Grigoriev, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute for Complex Problems of Cardiovascular Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Complex Problems of Cardiovascular Diseases</name>
      <address>
        <city>Kemerovo</city>
        <zip>650061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Yadlapati A, Groh C, Malaisrie SC, Gajjar M, Kruse J, Meyers S, Passman R. Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol. 2016 Mar;105(3):268-72. doi: 10.1007/s00392-015-0919-z. Epub 2015 Sep 18.</citation>
    <PMID>26384981</PMID>
  </reference>
  <reference>
    <citation>Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009 Aug 15;374(9689):565-76. doi: 10.1016/S0140-6736(09)60780-7. Review.</citation>
    <PMID>19683642</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Institute for Complex Problems of Cardiovascular Diseases, Russia</investigator_affiliation>
    <investigator_full_name>Sergey Mamchur</investigator_full_name>
    <investigator_title>Head of Department of Cardiovascular Disorders Diagnosis</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Mitral Valve Stenosis</keyword>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Biological Prosthesis</keyword>
  <keyword>Mitral Valve Replacement</keyword>
  <keyword>Cox-Maze Procedure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

